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Abstract
Follistatin, a physiological inhibitor of myostatin, induces a dramatic increase in
skeletal muscle mass, requiring the type 1 IGF-I receptor/Akt/mTOR pathway.
The aim of the present study was to investigate the role of IGF-I and insulin,
two ligands of the IGF-I receptor, in the follistatin hypertrophic action on skeletal
muscle. In a first step, we showed that follistatin increases muscle mass while
being associated with a downregulation of muscle IGF-I expression. In addition,
follistatin retained its full hypertrophic effect toward muscle in hypophysectomized
animals despite very low concentrations of circulating and muscle IGF-I.
Furthermore, follistatin did not increase muscle sensitivity to IGF-I in stimulating
phosphorylation of Akt but, surprisingly, decreased it once hypertrophy was
present. Taken together, these observations indicate that increased muscle IGF-
I production or sensitivity does not contribute to the muscle hypertrophy caused
by follistatin. Unlike low IGF-I, ...
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Follistatin, a physiological inhibitor of myostatin, induces a dramatic
increase in skeletal muscle mass, requiring the type 1 IGF-I receptor/
Akt/mTOR pathway. The aim of the present study was to investigate
the role of IGF-I and insulin, two ligands of the IGF-I receptor, in the
follistatin hypertrophic action on skeletal muscle. In a first step, we
showed that follistatin increases muscle mass while being associated
with a downregulation of muscle IGF-I expression. In addition,
follistatin retained its full hypertrophic effect toward muscle in hy-
pophysectomized animals despite very low concentrations of circu-
lating and muscle IGF-I. Furthermore, follistatin did not increase
muscle sensitivity to IGF-I in stimulating phosphorylation of Akt but,
surprisingly, decreased it once hypertrophy was present. Taken to-
gether, these observations indicate that increased muscle IGF-I pro-
duction or sensitivity does not contribute to the muscle hypertrophy
caused by follistatin. Unlike low IGF-I, low insulin, as obtained by
streptozotocin injection, attenuated the hypertrophic action of follista-
tin on skeletal muscle. Moreover, the full anabolic response to
follistatin was restored in this condition by insulin but also by IGF-I
infusion. Therefore, follistatin-induced muscle hypertrophy requires
the activation of the insulin/IGF-I pathway by either insulin or IGF-I.
When insulin or IGF-I alone is missing, follistatin retains its full
anabolic effect, but when both are deficient, as in streptozotocin-
treated animals, follistatin fails to stimulate muscle growth.
IGF-I; insulin; follistatin; myostatin; skeletal muscle hypertrophy
MYOSTATIN (Mstn), a member of the transforming growth factor
(TGF)- family expressed primarily in skeletal muscle, is a
negative regulator of skeletal muscle mass, as shown by the
increase in skeletal muscle mass and strength following Mstn
inhibition or gene deletion (28, 44). Among Mstn inhibitors,
follistatin (FS) and the soluble ligand-binding domain of ac-
tivin receptor type IIB fused to the Fc domain IgG (sActRIIB-
Fc) have been shown to bind and antagonize Mstn, leading to
a dramatic increase in muscle mass (3, 30, 37). The muscle
fiber hypertrophy induced by FS is due to increased protein
synthesis and requires the activation of Smad1/5 (63) and the
type I IGF-I receptor (IGF-IR)/Akt/mTOR pathway (34, 64).
IGF-I is known to be a major positive regulator of skeletal
muscle mass. Indeed, IGF-I overexpression specifically in
skeletal muscle increases skeletal muscle mass (13, 47),
whereas IGF-I knockout mice exhibit significant muscle hyp-
oplasia (42). Increased muscle IGF-I expression has been
reported in several models of muscle hypertrophy, such as
exercise, overloading, GH, and testosterone treatment (1, 20,
27, 39, 40). The role of IGF-I in the muscle hypertrophy caused
by Mstn inhibition is suggested by several pieces of evidence.
First, muscle mRNA expression and circulating concentrations
of IGF-I have been reported to be increased following Mstn
inhibition (35, 62, 64). Moreover, Mstn inhibition causes
muscle hypertrophy by increasing protein synthesis and satel-
lite cell activation, as IGF-I does (5, 6, 24, 58, 64). Finally,
muscle hypertrophy induced by both IGF-I overexpression and
Mstn inhibition requires the IGF-IR/Akt/mTOR pathway (8,
34, 51, 64). Taking these observations together, we hypothe-
sized that IGF-I might contribute to the muscle hypertrophy
caused by Mstn inhibition. To answer this question, we over-
expressed the hFS288 gene by electrotransfer in tibialis ante-
rior (TA) muscle of animals deficient in IGF-I and/or insulin
and treated or not by insulin or IGF-I. This work allowed us to
delineate the role of IGF-I and insulin in the skeletal muscle
hypertrophy caused by FS-induced Mstn inhibition.
MATERIALS AND METHODS
Animals
To assess the effect of Mstn inhibition on skeletal muscle mass and
IGF-I expression, we used C57BL/6 transgenic mice (mTr-FS) over-
expressing a human FS288 (hFS288) short form specifically in skel-
etal muscle (37) and their control wild-type (WT) littermates; FVB
Mstn knockout (Mstn KO) mice harboring a constitutive deletion of
the third Mstn exon (28) and their control WT littermates; and FVB
mice (Janvier Breeding, Le-Genest-Saint-Isle, France) treated by
intraperitoneal (ip) injection with sActRIIB-Fc (31) at a dose of 10
mg/kg twice a week for 14 days or with PBS (CTRL). The sAc-
tRIIB-Fc was prepared as described by Hoogaars et al. (30). All the
mice used were male, between 6 and 8 wk old, unless otherwise
stated. To assess the role of IGF-I in the muscle hypertrophy induced
by FS, we used hypophysectomized female Wistar rats purchased
from Charles River (Charles River Laboratories, France). Hypophy-
sectomy was performed at 5 wk of age and hypophysectomized
(HYPOX) animals were delivered to our animal quarters 7 days after
surgery with their control intact littermates (CTRL). To assess the
effect of FS on IGF-I sensitivity, we used 8-wk-old male mTr-FS mice
and their control WT littermates. To assess the effect of sActRIIB-Fc
on IGF-I sensitivity, we treated 8-wk-old C57Bl/6 male mice with
sActRIIB-Fc for 5 days. To explore the role of insulin in the muscle
hypertrophy induced by FS, we used streptozotocin (STZ)-injected
male Wistar rats. Animals (100–124 g) were provided by Janvier
Breeding at 4 wk of age and treated by STZ injection a week later. All
the animals were housed individually under controlled conditions of
lighting (12:12-h light-cycle) and temperature (22  2°C). They
received standard chow pellets and water ad libitum. The study was
conducted in accordance with the directives of and approved by the
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Animal Ethics Committee of the Catholic University of Louvain
(Brussels, Belgium).
Experimental Design
Experimental design 1: role of IGF-I in FS-induced muscle
hypertrophy. To assess the role of IGF-I in FS-induced muscle
hypertrophy, we used HYPOX rats. The experiment was started after
a 9-day adaptation period in our animal quarters. To attest the success
of hypophysectomy, changes in body weight were recorded during
this period. As expected, the body weight gain of HYPOX rats was
severely blunted compared with intact animals (18.0  2.1
vs. 94.9  7.4 g, n  6/group, P  0.001). During the adaptation
period, water was supplemented with 5% glucose and 0.9% NaCl.
Throughout the remainder of the experiment, the rats received water
containing 0.9% NaCl only and a hormonal replacement. HYPOX rats
(n  6) were given replacement therapy with L-thyroxine (10
g·kg1·day1; Sigma-Aldrich, Diegem, Belgium) and hydrocorti-
sone hemisuccinate (500 g·kg1·day1; Solu-Cortef, Pfizer, Oslo,
Norway) diluted in saline by daily subcutaneous injection (8:00 AM),
while CTRL rats (n 6) were injected with saline solution. One week
after the beginning of the hormonal treatment, TA muscles of HYPOX
and CTRL rats were transfected with the plasmid pM1-hFS288-c-myc
(left leg) and the control plasmid pM1 (right leg). TA muscles and
serum were collected 17 days after electroporation for assessment of
muscle hypertrophy and IGF-I concentrations.
Experimental design 2: effect of FS and sActRIIB-fc on skeletal
muscle IGF-I sensitivity. To investigate the effect of FS on IGF-I
sensitivity, mTr-FS and WT mice were fasted overnight, and muscle
and liver Akt phosphorylation (pAkt) was assessed after ip injection
of recombinant human IGF-I (Genentech, South San Francisco, CA).
One hundred microliters of a solution of IGF-I (200 or 400 g/kg
body wt) or 100 l of saline solution (vehicle, 0.9% NaCl) was
injected 15 min before the animals were euthanized. To investigate the
effect of the sActRIIB-Fc on IGF-I sensitivity, mice were treated with
two ip injections of 10 mg/kg sActRIIB-Fc (or same volume of PBS
for control animals) for 5 days. Animals were fasted overnight and
muscle pAkt was assessed after ip injection of recombinant human
IGF-I (Genentech). One hundred microliters of a solution of IGF-I
(400 g/kg body wt) or 100 l of saline solution (vehicle, 0.9% NaCl)
was injected 15 min before the mice were euthanized. Liver and
gastrocnemius (GC) muscles were collected for assessment of pAkt
by Western blotting analysis. Therefore, muscle IGF-I sensitivity was
explored in a transgenic model characterized by a marked hypertrophy
and in a nontransgenic model at the early stages of hypertrophy.
Experimental design 3: role of insulin in FS-induced muscle
hypertrophy. To explore the role of insulin in FS-induced muscle
hypertrophy, we used a model of STZ-induced diabetes. After a 7-day
adaptation period in our animal quarters, TA muscles of rats were
transfected with the plasmid pM1-hFS288-c-myc (left leg) and the
control plasmid pM1 (right leg). Three days after electroporation,
diabetes was induced by injecting STZ (Sigma-Aldrich, St. Louis,
MO) freshly prepared in 0.01 M citrate buffer, pH 4.5, at the dose of
60 mg/kg body wt into the tail vein. The CTRL group was injected
with an equivalent volume of 0.01 M citrate buffer, pH 4.5. Only rats
showing polydipsia, polyuria, glycosuria, and glycemia over 400
mg/dl were included in the experiment. Two days after STZ injection,
diabetic animals were randomized in two groups: one was infused
with insulin (STZINS group); the second group was not treated
(STZ group). Insulin treatment was achieved with two insulin im-
plants of Linplant (Linshin Canada, ON, Canada) placed subcutane-
ously in the interscapular region of STZINS rats. For implantation,
the three groups of rats (CTRL, STZ, STZINS) were anesthetized
with a mixture of 100 mg/kg ketamine (Anesketin; Pfizer, Oslo,
Norway) and 10 mg/kg xylazine hydrochloride (Rompun; Bayer,
Fernwald, Germany) administered by ip injection. Two implants were
placed in STZINS animals, while CTRL and STZ animals were
sham operated. Each implant delivered an average daily dose of 2 U
of insulin. Growth was assessed by body weight measurement. TA
muscles and serum were collected 14 days after electroporation for
assessment of muscle hypertrophy and IGF-I concentrations.
Experimental design 4: role of low IGF-I concentrations in the
attenuation of FS-induced muscle hypertrophy by insulinopenia. To
explore the role of low IGF-I concentrations in the attenuation of
FS-induced muscle hypertrophy by insulinopenia, we used the model
of STZ-induced diabetes described in experimental design 3. In this
experiment, IGF-I was infused in place of insulin. Two days after STZ
injection, diabetic animals were randomized in two groups: one was
infused with IGF-I (STZIGF-I group) and the second group was not
treated (STZ group). Recombinant human IGF-I Increlex, generously
given by Ipsen (Ipsen Biopharmaceuticals, Merelbeke, Belgium) was
administrated at a dose of 3 mg·kg1·day1 with an Alzet osmotic
pump (model 2M2L; Durect, Cupertino, CA) implanted subcutane-
ously in the interscapular region of STZIGF-I rats. For implantation,
the three groups of rats (CTRL, STZ, STZIGF-I) were anesthetized
with a mixture of 100 mg/kg ketamine (Anesketin; Pfizer, Oslo,
Norway) and 10 mg/kg xylazine hydrochloride (Rompun; Bayer,
Fernwald, Germany) administered by ip injection. One pump filled
with IGF-I was placed in STZIGF-I animals, while CTRL and STZ
animals received a pump filled with vehicle (0.05 M acetate buffer,
pH 5.4). Growth was assessed by body weight measurement. TA
muscles were collected 14 days after electroporation for assessment of
muscle hypertrophy.
Expression Plasmids and DNA Preparation
A pM1-hFS288 c-myc plasmid coding for the human FS containing
288 amino acids was constructed as previously described (24, 34).
Empty pM1 was used as a control plasmid. Plasmids were amplified
in Escherichia coli top 10 F= (Invitrogen, Carlsbad, CA) and purified
with an EndoFree plasmid giga kit (Qiagen, Valencia, CA). Plasmids
were stocked at 80°C. The day before injection, 100 g of plasmid
was lyophilized and resuspended in 100 l of 0.9% NaCl solution.
DNA Electrotransfer
Each animal was anesthetized with a mixture of 100 mg/kg ket-
amine (Anesketin) and 10 mg/kg xylazine hydrochloride (Rompun)
administered by ip injection. Ten microliters of plasmid solution (1
g/l) was injected into 10 different sites (total volume per muscle
100 l) in each TA muscle, and the muscles were then electroporated
using the electroporation conditions described previously (53). The
animals were euthanized 14–17 days after electroporation.
Animal Euthanasia and Biological Sample Collection
All the animals were euthanized by decapitation after CO2 admin-
istration, and blood was collected from the trunk vessels. TA muscles
were dissected, and a transverse slice of 0.5-cm thickness was fixed
with buffered formalin for 48 h and embedded in paraffin for mor-
phological analysis. The remaining ends of the TA muscles were
frozen in liquid nitrogen for ELISA and mRNA analysis. GC muscles
were removed and frozen in liquid nitrogen for ELISA, mRNA, and
Western blot analysis.
mRNA Analysis by Real-Time Quantitative PCR
Total RNA was isolated from the TA muscle using Tri Reagent as
described by the manufacturer. Recovery was 1 g/mg of TA muscle.
Reverse transcription and real-time quantitative PCR were done as
previously described (18). Accession numbers for the sequences and
primers used were as follows: IGF-I: AH002176 (CAGGCTATG-
GCTCCAGCAT-GGAAGCAACACTCATCCACA) IGF-IR:
X044434.1 (TCATGCCTTGGTCTCCTTGTCCTT-GTCACTTC-
CTCCATGCGGTAAATTTCG), IGFBP-5: NM_010518.2 (TC-
CGAACAAGGCCCCTGCCG-GCTGTCGAAGGCGTGGCACT),
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MAFbx/atrogin-1: NM_026346.3 (CCATCAGGAGAAGTGGATC-
TATGTT-GCTTCCCCCAAAGTGCAGTA), and REDD1:
NM_029083.2 (AGACTCCTCATACCTGGATGGG-AGCTGCAT-
CAGGTTGGCAC), and GAPDH, AF106860 (TGCACCACCAACT-
GCTTA-GGATGCAGGGATGATGTTC), used as the reporter gene.
Primers were tested to avoid primer dimers, self-priming formation, or
unspecific amplification. The primers were designed to have standard-
ized optimal PCR conditions. We confirmed that the expression values
of GAPDH normalized to RNA were not affected by Mstn inhibition
in our different animal models. This was confirmed at the protein
level, as illustrated on the blots presented in Fig. 3A, showing that the
abundance of GAPDH protein was not affected by FS overexpression,
making GAPDH a valuable control.
Muscle and Circulating IGF-I Concentrations
One hundred milligrams of TA muscle, previously pestled in liquid
nitrogen, was homogenized with Ultraturrax (IKALabortechnik,
Staufen, Germany) in 1 ml of pH 7.4 1	 PBS (130 mM NaCl, 17 mM
Na2HPO4, and 3 mM NaH2PO4) and stored overnight at20°C. After
two freeze-thaw cycles were performed to break the cell membranes,
the homogenates were centrifuged for 5 min at 5,000 g. The super-
natant was removed and stored at 80°C until the assay. Blood was
allowed to clot for 15 min at room temperature before centrifuging for
10 min at 2,000 g. Serum was removed and stored at 80°C until the
assay. Muscle and circulating levels of IGF-I peptide were determined
using Quantikine ELISA Mouse/Rat according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN).
Western Blots
Muscle proteins of GC muscle were homogenized in ice-cold pH
7.0 buffer containing 20 mM Tris, 270 mM sucrose, 5 mM EGTA, 1
mM EDTA, 1 mM sodium orthovanadate, 50 mM -glycerophos-
phate, 5 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM
DTT, 1% (vol/vol) Triton X-100, and 10% protease inhibitor cocktail
(Roche Applied Science, Belgium). Homogenates were centrifuged at
10,000 g for 10 min at 4°C, and supernatants were immediately stored
at 80°C. Equal amounts of proteins were resolved by sodium
dodecyl sulfate-polyacrylamide gel 10% electrophoresis and trans-
ferred to PVDF membranes. Membranes were probed with the fol-
lowing primary antibodies: anti-phospho-Akt (Ser473, 1:2,000; Cell
Signaling Technology, Leiden, Netherlands), anti-Akt (1:2,000; Mil-
lipore, Overijse, Belgium), and anti-GAPDH (1:40,000; Cell Signal-
ing Technology). Membranes were then incubated with a horseradish
peroxidase-coupled secondary antibody (Cell Signaling Technology)
and developed using Enhanced Chemiluminescence (ECL) Western
Blotting Detection System Plus (GE Healthcare, Belgium). Developed
film was scanned and analyzed as previously described (54). All
results were normalized for the signal to GAPDH protein.
Histological Analysis of Muscle
Serial sections (5 m thick) were cut and mounted on glass slides
(Superfrost Plus; Menzel-Glaser, Braunschweig, Germany). FS-c-myc
was detected by immunohistochemistry with rabbit polyclonal anti-
c-myc as previously described (24). Fiber cross-sectional areas (CSA)
were measured with a microscope Axio-Star (Carl Zeiss, Okerkochen,
Germany) coupled to a Zeiss Axiocam digital camera MRc and to
image analyzer software (Axiovision software v. 4.7, Carl Zeiss). To
evaluate the effect of FS on muscle fiber CSA, all the positive muscle
fibers in the TA transfected with the FS gene were measured. Two
hundred negative fibers, randomly chosen in the contralateral TA
transfected with insertless plasmid (pM1), were measured and con-
sidered as controls.
Statistical Analysis
Results are presented as means  SE. Statistical analyses were
performed using a one-way ANOVA followed by a Bonferroni
multiple comparison test or unpaired t-test to compare muscles from
different animals undergoing different experimental conditions. Inter-
actions between FS and hypophysectomy, as well as between FS/
sActRIIB and IGF-I injection, were assessed using a two-way
ANOVA followed by a Bonferroni posttest. Fiber CSA distribution
statistical analysis was performed using a 
2 Pearson test. Statistical
significance was set at P  0.05.
RESULTS
Muscle Hypertrophy Caused by Mstn Inhibition Is
Associated with Decreased Muscle IGF-I mRNA and Peptide
Levels
IGF-IR mediated-signaling is required for FS to promote
muscle hypertrophy (34). Since the IGF-IR is activated primar-
ily by IGF-I, we investigated whether the muscle hypertrophy
induced by Mstn inhibition is mediated by increased muscle
IGF-I expression. First, muscle IGF-I mRNA levels were
assessed in TA and GC muscles from different animal models
of muscle hypertrophy induced by Mstn inhibition: mTr-FS,
Mstn KO, and sActRIIB-Fc-treated mice. Surprisingly, we
found that muscle IGF-I expression was systematically reduced
in mTr-FS, Mstn KO, and sActRIIB-Fc-treated mice compared
with their control littermates (Fig. 1B) in contrast to muscle
mass (Fig. 1A). Interestingly, muscle IGF-I mRNA levels were
already decreased (44%, P  0.05) in 4-wk-old mTr-FS
mice, namely before any muscle hypertrophy. Then, the IGF-I
peptide concentrations were determined in the TA muscle of
mTr-FS. We confirmed that FS overexpression decreased not
only IGF-I mRNA but also peptide in the skeletal muscle
(mTr-FS, 41%; 9  1 vs. WT, 16  2 ng/g, n  8/group,
P  0.05; Fig. 1C). In the other animal models of Mstn
inhibition, we are confident that changes in muscle IGF-I
mRNA translated in parallel the changes in muscle IGF-I
peptide. Indeed, in several animal models we observed parallel
changes in IGF-I mRNA and peptide in skeletal muscle (data
not shown). Circulating IGF-I concentrations were not affected
by FS overexpression (Fig. 1D).
FS Induces Muscle Hypertrophy in HYPOX Animals Despite
Very Low Concentrations of Circulating and Muscle IGF-I
To investigate the role of IGF-I in FS-induced skeletal
muscle hypertrophy, we overexpressed FS by DNA electro-
transfer in the TA muscle of HYPOX rats, characterized by
very low concentrations of IGF-I. The IGF-I mRNA levels in
the TA muscle were modestly decreased after hypophysectomy
(22%, P  0.01). However, both muscle and circulating
concentrations of the IGF-I peptide were severely reduced,
respectively by 90% (pM1-transfected muscle: 2  1 vs. 15 
1 ng/g, n  6/group, P  0.001) and by 95% (52  3 vs.
1,097  57 ng/ml, n  6/group, P  0.001) after hypophy-
sectomy (Fig. 2, A and B). Interestingly, despite very low
concentrations of muscle and circulating IGF-I, FS overexpres-
sion caused the same increase of muscle mass in HYPOX rats
(23%, 217 6 vs. 177 5 mg, P 0.001) and in their intact
CTRL littermates (28%, 448  27 vs. 351  25 mg, P 
0.001, n  6/group; Fig. 2C) 17 days after electroporation.
Furthermore, FS overexpression induced an even larger rise of
fiber CSA in HYPOX (102%, 1,766  166 vs. 877  39
m2, P  0.001) than in CTRL rats (57%, 2,420  175 vs.
1,552  102 m2, P  0.001, n  6/group; Fig. 2D). These
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results demonstrate that FS retains its full hypertrophic effect
toward muscle despite very low concentrations of circulating
and muscle IGF-I.
FS Overexpression Does Not Increase Skeletal Muscle IGF-I
Sensitivity
The ability of FS to exert its full anabolic effect, even in the
presence of very low IGF-I concentrations, suggests two hy-
potheses: either FS overexpression increases the muscle sen-
sitivity to the anabolic effect of IGF-I, or, alternatively, IGF-I
is not required for FS to promote muscle hypertrophy. The first
hypothesis is suggested by the demonstration made previously
that Mstn inhibition increases the insulin-stimulated activation
of Akt and glucose uptake in skeletal muscle (29, 45, 66, 67).
To investigate whether FS overexpression enhances IGF-I
sensitivity in skeletal muscle, we assessed the activation of the
protein kinase Akt, a downstream target of the IGF-IR crucial
for the anabolic action of FS (34), after injection of graded
doses of IGF-I into mTr-FS and WT mice (Fig. 3). Activation
of IGF-I signaling normally increases the phosphorylation state
of Akt, as seen in GC muscle from WT mice (4.4  0.4-fold,
IGF-I 400 g/kg vs. 1  0.4-fold, Saline, P  0.001, n 
3–4/group). Unexpectedly, the increased phosphorylation of
Akt in response to IGF-I was almost abolished in GC muscle
of mTr-FS mice (1.8  0.6-fold, IGF-I 400 g/kg vs. 1.1 
0.1-fold, Saline, P  0.05; Fig. 3, A, B, and C). In contrast,
IGF-I injection (400 g/kg) activated Akt to a similar extent in
the liver from mTr-FS and WT mice (3.0  0.6-fold vs. 3.1 
0.5-fold, NS, n  3–4/group; Fig. 3, D, E, and F). Levels of
total Akt protein were increased in response to Mstn inhibition,
as already reported (26, 45, 66). Taken together, our observa-
tions unravel a muscle-specific decrease of the IGF-I signaling
in mTr-FS mice. To examine the mechanisms for this resis-
tance, we assessed the expression of potential candidate pro-
teins that might limit IGF-I responsiveness of the muscle in
mTr-FS mice. The muscle hypertrophy caused by FS overex-
pression was associated with an increase in muscle IGF-
binding protein (IGFBP)-5 mRNA levels (64%, P  0.001)
together with a decrease in IGF-IR mRNA levels (24%, P 
0.01), supporting the hypothesis of a decreased muscle
sensitivity to IGF-I. Although muscle IGF-I sensitivity is
decreased in adult mTr-FS mice, the possibility still exists
that an increase in muscle IGF-I sensitivity might play a role
at the early stages of hypertrophy. To test this hypothesis,
we assessed the muscle IGF-I sensitivity caused by Mstn
inhibition using mice treated with sActRIIB-Fc for a brief
period as a model of incipient hypertrophy. In these condi-
tions, the increase of Akt phosphorylation induced by IGF-I
Fig. 1. Muscle hypertrophy caused by myostatin (Mstn) inhibition is associated with decreased muscle IGF-I mRNA and peptide levels. A and B: muscle weight
and muscle IGF-I mRNA levels were assessed in tibialis anterior (TA) muscle of C57Bl/6 mTr-FS (follistatin) vs. WT mice (n 11/group) and FVB sActRIIB-Fc
(soluble ligand binding domain of activin receptor type IIB fused to Fc domain IgG)-treated vs. saline-treated mice (n  6/group) and in gastrocnemius (GC)
muscle of FVB Mstn KO vs. WT mice (n  7/group). C and D: IGF-I peptide concentrations were assessed in TA muscle (C) and in the circulation (D) of WT
(open column) and mTr-FS (filled column) mice (n 8/group). sActRIIB-Fc, soluble ligand-binding domain of activin recteptor IIB fused to the Fc domain IgG.
Results are expressed as means  SE. Statistical analysis was performed using unpaired t-test (P  0.05; *P  0.05, ***P  0.001).
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was not affected by the sActRIIB-Fc pretreatment (7.9 
10.7-fold vs. 7.2  1.4-fold, NS, n  3– 4/group; Fig. 4, A,
B, and C). This last observation supports the view that the
decreased muscle IGF-I sensitivity observed in mTr-FS is
secondary to muscle hypertrophy. Taken together, our ob-
servations indicate that the muscle hypertrophy caused by
Mstn inhibition does not result from increased IGF-I sensi-
tivity.
FS-Induced Muscle Hypertrophy Is Attenuated in STZ-
Diabetic Animals
Since the IGF-IR can be activated by either IGF-I or
insulin, we investigated the role of insulin in skeletal muscle
hypertrophy induced by FS overexpression. To investigate
the role of insulin in FS-induced skeletal muscle hypertro-
phy, we overexpressed FS by DNA electrotransfer in the TA
muscle of STZ-induced diabetic rats, characterized by low
insulin concentrations. To attest the success of STZ injec-
tion, glycemia was determined 2 days after STZ injection
and at the end of the experiment. As expected, the glycemia
of STZ rats was markedly increased compared with CTRL
(581  11 vs. 116  5 mg/dl, n  8/group, P  0.001) and
restored to normal in STZ rats treated with insulin implants
(115  7 vs. 116  5 mg/dl, n  8/group, NS; Fig. 5A).
Concentrations of IGF-I peptide were significantly de-
creased in STZ rats compared with CTRL rats both in the
circulation (38%, 920  73 vs. 1,476  69 ng/ml, n 
8/group, P  0.001) and in the muscle (51%, pM1-
transfected muscle: 14  1 vs. 30  3 ng/g, n  8/group, P
 0.001; Fig. 5, C and D). They were restored to normal
levels in STZ rats treated with insulin implants both in the
circulation (1,518  54 vs. 1,476  69 ng/ml, n  8/group,
NS) and in the muscle (pM1-transfected muscle: 28  3 vs.
30  3 ng/g, n  8/group, NS; Fig. 5, C and D). In contrast
to hypophysectomy, insulinopenia decreased the FS-induced
hypertrophy. Indeed, FS overexpression for 17 days induced
a lower rise of fiber CSA in STZ rats (33%, 2,440  166
vs. 1,835  80 m2, P  0.05) than in CTRL rats (57%,
3,191  150 vs. 2,037  56 m2, P  0.001; Fig. 5E). To
examine some potential mechanisms for this attenuation, we
assessed the expression of MAFbx/atrogin-1 and REDD1,
two factors that inhibit muscle protein synthesis (14, 19) and
might thus limit the responsiveness to FS. The expression of
MAFbx/atrogin-1 and REDD1 was significantly increased in
the muscle of STZ animals (respectively in pM1-transfected
muscle: 2.7-fold, P  0.001 and 1.9-fold, P  0.001),
supporting the idea of decreased protein synthesis in re-
sponse to FS in the case of insulinopenia. Moreover, insulin
implants in STZ rats restored the full hypertrophic effect of
FS as assessed by the fiber CSA (60%, 3,501  199 vs.
2,181  97 mg, P  0.001) as well as the baseline
expression levels of MAFbx/atrogin-1 and REDD1.
Fig. 2. FS induces muscle hypertrophy in hypophysectomized (HYPOX) animals despite very low concentrations of circulating and muscle IGF-I. A: circulating
concentrations of IGF-I were assessed in CTRL (open column) and in HYPOX (filled column) rats (n  6/group). Results are expressed as means  SE.
Statistical analysis was performed using unpaired t-test (***P  0.001). B–D: muscle concentrations of IGF-I peptide (B), TA muscle weight (C), and fiber
cross-sectional area (CSA; D) were assessed 17 days after transfection of pM1 (open column) or pM1-hFS288 (filled column) in CTRL and HYPOX rats (n 
6/group). Results are expressed as means  SE. Statistical analysis was performed using 2-way ANOVA (muscle IGF-I concentrations: FS effect, NS, HYPOX
effect, P 0.001, interaction, NS; TA weight: FS effect, P 0.01, HYPOX effect, P 0.001, interaction, NS; fiber CSA: FS effect, P 0.001, HYPOX effect,
P  0.001, interaction, NS) and Bonferroni posttest (***P  0.001 vs. contralateral muscle; XXXP  0.001 vs. CTRL pM1 muscle; YYYP  0.001 vs. CTRL
pM1-hFS288 c-myc muscle).
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IGF-I Treatment Restores the Full Hypertrophic Effect of FS
in STZ-Diabetic Animals
To investigate whether restoration of the full anabolic effect
of FS was due to insulin infusion or to normalization of IGF-I
or glycemia, we administrated IGF-I to STZ rats electroporated
with FS. IGF-I infusion restored the body growth of STZ rats
without normalizing glycemia (Fig. 6, A and B). Furthermore,
we showed that IGF-I treatment also restored to normal the
FS-induced muscle hypertrophy as assessed by the measure-
ment of the fiber CSA (STZIGF-I: 59%, P  0.001 vs.
STZ: 28%, P  0.05; Fig. 6C). Accordingly, we demon-
strated that FS does not exert its full anabolic effect in the
absence of insulin associated with a decrease of IGF-I. Inter-
estingly, in the case of insulinopenia, IGF-I infusion could
restore the FS hypertrophy and therefore compensate for the
lack of insulin despite the persistence of hyperglycemia.
DISCUSSION
Our study investigated the role of IGF-I and insulin in
muscle hypertrophy caused by FS overexpression. Indeed, we
showed in a previous experiment that the hypertrophic action
of FS on skeletal muscle requires the activation of the IGF-IR/
Akt/mTOR pathway (34). Since the IGF-IR can be activated
either by IGF-I or by insulin and because insulin signaling
could also contribute to the regulation of skeletal muscle mass
(48), we specifically investigated the role of these ligands in
FS-induced muscle hypertrophy. Our results show that FS
causes a decrease in muscle IGF-I expression, which contrasts
with the marked muscle hypertrophy. Moreover, FS retains its
full anabolic effect toward muscle even in the presence of very
low concentrations of IGF-I. Finally, FS does not increase
muscle sensitivity to IGF-I in stimulating phosphorylation of
Akt but, surprisingly, decreases it once hypertrophy is present.
Fig. 3. FS does not increase muscle IGF-I sensitivity. A–C: increase of muscle pAkt (Ser473) induced by acute IGF-I injection (200 g/kg, gray column, or 400
g/kg, filled column vs. saline, open column) is severely blunted in mTr-FS mice (n 3–4/group). Muscle activation of Akt was assessed by Western blot analysis
(A) and densitometric analysis of pAkt/GAPDH (B) and total-Akt/GAPDH (C). Results are expressed as means  SE. Statistical analysis was performed using
2-way ANOVA (pAkt/GAPDH: IGF-I effect, P  0.01, mTr-FS effect, P  0.01, interaction, P  0.05; total-Akt/GAPDH: IGF-I effect, NS, mTr-FS effect,
P  0.001, interaction, NS) and Bonferroni posttest (***P  0.001 vs. saline). D–F: increase in liver pAkt (Ser473) induced by acute IGF-I injection (200 g/kg,
gray column, or 400 g/kg, filled column vs. saline, open column) is similar in WT and mTr-FS mice (n  3–4/group). Liver activation of Akt was assessed by
Western blot analysis (D) and densitometric analysis of pAkt/GAPDH (E) and total-Akt/GAPDH (F). Results are expressed as means  SE. Statistical analysis
was performed using 2-way ANOVA (pAkt/GAPDH: IGF-I effect, P  0.01, mTr-FS effect, NS, interaction, NS; total-Akt/GAPDH: IGF-I effect, NS; mTr-FS
effect, NS, interaction, NS) and Bonferroni posttest (*P  0.05 vs. saline).
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Taken together, our observations indicate that increased IGF-I
production or sensitivity does not contribute to the muscle
hypertrophy caused by FS. In contrast, insulinopenia induced
by STZ injection attenuates the hypertrophic action of FS on
skeletal muscle. Moreover, the full anabolic response to FS can
be restored in this condition by insulin but also by IGF-I
infusion. Therefore, our results indicate that insulin is required
for the anabolic action of FS but can be substituted by IGF-I in
the case of insulinopenia.
The regulation of IGF-I during the muscle hypertrophy
caused by Mstn inhibition remains debated. Such regulation
has been suggested by the observation of increased muscle
mRNA expression and circulating concentrations of IGF-I in
response to Mstn inhibition (35, 62, 64). However, some
authors have also reported a decrease in muscle IGF-I mRNA
expression in the same conditions (12, 23, 62). The reasons for
this discrepancy are unclear. They might result from the choice
of primers for qRT-PCR, which may assess different IGF-I
mRNA transcripts (7). In our work, we used specific primers
located on exons 3 and 4 to measure the expression levels of all
IGF-I mRNA transcripts, and not only the mechanogrowth
factor (MGF) (65). Moreover, the approaches to inhibit Mstn
differ from one study to another. It is known that FS and
sActRIIB-Fc inhibit both Mstn and activin A (ActA) (24, 38,
57) in contrast to a Mstn KO model in which only Mstn is
inactivated. Finally, the mechanism of muscle hypertrophy
caused by Mstn inhibition may result from fiber hypertrophy
and/or hyperplasia according to the stage of development at
which the inhibition occurs (28, 44). In this study, we assessed
IGF-I mRNA expression in different Mstn inhibition models:
prenatal deletion of the Mstn gene (Mstn KO), resulting in fiber
hyperplasia (23); postnatal inhibition of Mstn and ActA by
sActRIIB-Fc resulting in fiber hypertrophy (11); and prenatal
inhibition of Mstn and ActA by FS overexpression, resulting in
fiber hyperplasia and hypertrophy (37). In all conditions, we
showed that muscle IGF-I expression is systematically reduced
regardless of the approach used to inhibit Mstn. Moreover, we
demonstrated that this decrease of muscle IGF-I mRNA
levels is correlated with low muscle IGF-I peptide concen-
trations. The possibility that this decrease in muscle IGF-I
peptide results from a decrease in extracellular matrix as
observed in response to Mstn inhibition (9, 10, 60) is
unlikely. Indeed, immunohistochemical studies showed that
IGF-I protein is localized mainly in muscle fiber and not in
extracellular matrix (40).
The role of IGF-I during the muscle hypertrophy caused by
Mstn inhibition has never been investigated. Not only does
IGF-I by itself increase skeletal muscle mass (2, 13, 47), but its
increased muscle expression in response to several anabolic
stimuli suggests that it may contribute to muscle hypertrophy
in many conditions (overloading, testosterone, overexpression
of PGC-14, etc.) (1, 20, 39, 40, 52). Evidence suggests that
IGF-I might contribute to FS-induced muscle hypertrophy.
Indeed, FS induces muscle hypertrophy by increasing protein
synthesis and satellite cell activation, as IGF-I does (5, 6, 24,
58). In addition, Mstn inhibition stimulates the Akt/mTOR/
S6K pathway, the pathway mainly responsible for the muscle
hypertrophy caused by IGF-I (41, 45, 51). Finally, MKR mice,
which are characterized by downregulation of muscle IGF-IR,
are resistant to the anabolic effect of FS (34). To investigate the
role of IGF-I in FS-induced hypertrophy, we used a model of
HYPOX rats. Indeed, this model had already been successfully
used to assess the role of IGF-I in testosterone- and load-
induced skeletal muscle hypertrophy (25, 56). Furthermore,
this animal model is probably the only nonlethal model char-
acterized by a profound and global IGF-I deficiency (4, 42, 49).
This model allowed us to demonstrate that the GH-IGF-I axis
is not required for FS to exert its anabolic action. Since
HYPOX animals still present very low concentrations of IGF-I,
we cannot exclude the possibility that these low IGF-I concen-
trations were sufficient to allow the FS-induced muscle hyper-
trophy. However, these concentrations were clearly not suffi-
cient to support body and muscle growth. Except if FS in-
creases the muscle sensitivity to the anabolic action of IGF-I,
the role of IGF-I in the FS-induced muscle hypertrophy is not
supported by our observations.
The possibility for FS to increase muscle sensitivity to IGF-I
is suggested by some reports showing that Mstn inhibition
Fig. 4. sActRIIB-Fc does not increase muscle IGF-I sensitivity. A–C: increase
of muscle pAkt (Ser473) induced by acute IGF-I injection (400 g/kg, filled
column, vs. saline, open column) is not affected in sActRIIB-Fc-treated mice
(n  3–4/group). Muscle activation of Akt was assessed by Western blot
analysis (A) and densitometric analysis of pAkt/GAPDH (B) and total-Akt/
GAPDH (C). Results are expressed as means  SE. Statistical analysis was
performed using 2-way ANOVA (pAkt/GAPDH: IGF-I effect, P  0.001,
sActRIIB effect, NS, interaction, NS; total-Akt/GAPDH: IGF-I effect, NS,
sActRIIB effect, NS, interaction, NS) and Bonferroni posttest (***P  0.001
vs. saline).
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increases the insulin-stimulated activation of Akt and glucose
uptake in skeletal muscle (29, 45, 66, 67). Although IGF-I and
insulin signaling pathways share multiple intracellular media-
tors, no study has investigated the muscle IGF-I sensitivity in
case of Mstn inhibition. It has been demonstrated that IGF-I
and FS promote muscle hypertrophy via the Akt/mTOR sig-
naling pathway leading to the stimulation of protein synthesis
(34, 51). Therefore, since Akt is an important mediator in the
hypertrophy process, we assessed its activation after injection
of IGF-I to investigate the IGF-I sensitivity of the muscle from
mTr-FS mice. For the first time, our results demonstrated a
decreased IGF-I sensitivity of muscle overexpressing FS. This
absence of Akt activation in response to IGF-I contrasts with
the increased pAkt in response to insulin observed in Mstn KO
mice (29). The mechanisms operational in this reduction of
muscle sensitivity to IGF-I are unknown. The possibility has
been suggested for Mstn to interact with the IGF signaling by
modulating the local expression of IGFBPs (16, 62). Interest-
ingly, we observed an increase of muscle IGFBP-5 expression
in response to Mstn inhibition. Since IGFBP-5 has been shown
to inhibit the IGF-I action towards muscle cells (33, 46, 59), its
induction by FS could reduce the local bioavailability of IGF-I
and attenuate the IGF-I action specifically in the skeletal
muscle and not in the liver. Furthermore, as previously de-
scribed (34), we also showed a decrease in the muscle IGF-IR
mRNA expression in response to Mstn inhibition. Therefore,
Fig. 5. FS-induced muscle hypertrophy is attenuated in STZ-diabetic animals. A: glycemia is significantly higher in STZ-treated rats (filled column) vs. CTRL
rats (open column) and is restored to normal levels in STZ rats treated with insulin implants (gray column, ***P  0.001 vs. CTRL, n  8–10/group). B:
evolution of body weight of CTRL (—), STZ-treated rats (—), and STZ rats treated with insulin (. .). Three days after DNA injection (a), rats were treated with
STZ (60 mg/kg) (b); 2 days later rats were treated with insulin (4U/day, ***P  0.001 vs. CTRL) (c). C and D: circulating (C) and muscle (D) IGF-I
concentrations are significantly decreased in STZ rats vs. CTRL rats and are restored to normal levels in STZ rats treated with insulin implants. Fiber CSA (E)
were assessed 14 days after transfection of pM1 (open column) or pM1-hFS288 (filled column) in CTRL, STZ, and STZINS rats (n  8–10/group). Results
are expressed as means  SE. Statistical analysis was performed using 1-way ANOVA and Bonferroni posttest (*P  0.05, ***P  0.001 vs. contralateral
muscle; XXXP  0.001 vs. CTRL pM1 muscle; YYYP  0.001 vs. CTRL pM1-hFS288).
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we cannot exclude that the decrease of muscle IGF-I sensitivity
observed in mTr-FS mice might result from a down regulation
of the muscle IGF-IR. Finally, alterations in muscle vascular-
ization in mTr-FS might also impair the access of IGF-I to the
membrane IGF-IR. Indeed, Mstn inhibition has been shown to
decrease muscle capillary density together with VEGF expres-
sion (31, 50). However, this hypothesis is unlikely, as this
decrease in muscle capillary density does not seem to impair
the stimulation of muscle Akt and glucose uptake by insulin
(29). Collectively, these results lead thinking that in response
to FS, muscle cells put in place mechanisms inhibiting the
IGF-I actions as a negative feedback loop to prevent greater
hypertrophy. This view is supported by the normal muscle
IGF-I sensitivity observed at early stages of hypertrophy in-
duced by the sActRIIB-Fc, suggesting that the decreased mus-
cle IGF-I sensitivity observed in mTr-FS mice is secondary to
muscle hypertrophy. Therefore, neither increased IGF-I pro-
duction nor increased IGF-I sensitivity contribute to the muscle
hypertrophy caused by FS.
Since the IGF-IR can be activated by IGF-I but also insulin,
we investigated the role of these ligands in the skeletal muscle
hypertrophy induced by FS. Our results show that low insulin,
unlike low IGF-I, severely blunts the FS-induced muscle hy-
pertrophy. This conclusion is also suggested by the results of
Wang et al. (61), reporting a reduced hypertrophic effect of
sActRIIB-Fc treatment in mice treated with STZ. Since muscle
hypertrophy induced by FS results mainly from a stimulation
of protein synthesis via the Akt/mTOR pathway (34, 58, 64),
insulinopenia could impair the effect of FS through altered
protein synthesis. This hypothesis is supported by several
observations. First, STZ decreases the activation of the Akt/
mTOR pathway (32) required for the anabolic effect of FS
(34). Second, insulinopenia stimulates the muscle expression
of REDD1, a well-recognized translational repressor inhibiting
Akt/mTOR signaling (21, 32), and MAFbx/atrogin-1 (17), a
muscle-specific ubiquitin ligase that targets for degradation the
protein translation initiation factor eIF3f (14, 15, 36). As we
showed an increase in REDD1 and MAFbx/atrogin-1 mRNA
expression, it seems that the anabolic effect of FS toward
muscle requires the action of insulin, probably to allow stim-
ulation of protein synthesis.
Restoration of the full anabolic effect of FS by IGF-I in STZ
animals, despite the persistence of hyperglycemia, indicates
that IGF-I may substitute for the anabolic properties but not for
the hypoglycemic effect of insulin. A Similar observation was
already made for bone growth. Indeed, IGF-I treatment re-
stored the longitudinal bone growth of STZ-treated rats without
normalization of glycemia (55). The fact that FS retains its
hypertrophic action in IGF-I-treated STZ animals despite the
presence of hyperglycemia suggests that the failure of FS to
stimulate muscle hypertrophy in STZ animals is not due to
glucose toxicity. However, the observation that IGF-I restores
growth in STZ-diabetic animals without restoring normogly-
cemia cannot be interpreted as the result of the IGF-I binding
to the IGF-IR. Indeed, our work did not investigate which,
IGF-IR or insulin receptor (INS-R), is required for FS to exert
its anabolic action. Although the ligands insulin and IGF-I can
substitute one for the other, this phenomenon does not seem to
apply to their receptors. Indeed, deletion of the INS-R (48),
like the IGF-IR (43), is associated with decreased muscle
growth, suggesting that both receptors are required for proper
physiological muscle growth. Moreover, expression of the
dominant-negative form of IGF-IR, or MKR, which inhibits
the FS-induced muscle hypertrophy (34), impairs both insulin
and IGF-I signaling in muscle due to hybrid receptor formation
(22). Therefore, since the two receptors are mandatory for
proper physiological muscle growth, we cannot specify which
of them, INS-R or IGF-IR, is involved in the FS-induced
muscle hypertrophy. Ultimately, our study establishes the need
of insulin or IGF-I for the full anabolic effect of FS toward
skeletal muscle. When insulin or IGF-I alone is missing, FS
retains its full anabolic effect. But, when both are deficient, as
Fig. 6. IGF-I treatment restores FS-induced muscle fiber hypertrophy in
STZ-diabetic animals. A: glycemia is significantly higher in STZ-treated rats
and STZ rats treated with IGF-I vs. CTRL rats (**P  0.01, ***P  0.001 vs.
CTRL; n  3/group). B: evolution of body weight of CTRL (—), STZ-treated
(—), and STZ rats treated with IGF-I (. .). Three days after DNA injection (a),
rats were treated with STZ (60 mg/kg) (b); 2 days later, rats were treated with
IGF-I (3 mg·kg1·day1) (c). C: fiber CSA were determined 14 days after
transfection of pM1 (open column) or pM1-hFS288 (filled column) in CTRL,
STZ, and STZIGF-I rats (n  3/group). Results are expressed as means 
SE. Statistical analysis was performed using 1-way ANOVA and Bonferroni
posttest (**P  0.01 vs. contralateral muscle; YP  0.05 vs. CTRL
pM1-hFS288).
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in STZ animals, FS fails to simulate muscle growth. In phys-
iological conditions, both hormones probably allow FS to
promote muscle hypertrophy. Thus, IGF-I is not absolutely
required for FS to induce skeletal muscle hypertrophy except in
case of insulinopenia.
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